BME$MT
ArcelorMittal · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
ODDITY Tech beats Q2 with $241M revenue up 25% and raises full-year outlook ahead of Brand 3 launch
ODDITY Tech reported second quarter 2025 net revenue of $241.1 million, up 25% year over year, with gross profit of $174.4 million and a 72.3% gross margin. Net income was $49.3 million (20.4% margin) versus $45.5 million in Q2 2024, while adjusted net income rose 12% to $57.1 million and adjusted EBITDA increased 12% to $70.0 million. Adjusted diluted EPS was $0.92 versus $0.82. Online direct-to-consumer revenue grew to $235.2 million, 98% of total sales. The company completed a $600 million zero-coupon exchangeable note offering and ended the quarter with $815 million in cash, deposits, and marketable securities. Management raised full-year 2025 guidance to $799–804 million in revenue and $160–162 million in adjusted EBITDA.
- Net revenue grew 25% to $241.1 million, beating guidance, with gross margin of 72.3% and adjusted EBITDA of $70.0 million
- Adjusted diluted EPS was $0.92 versus $0.82; online DTC revenue was $235.2 million, 98% of total
- Completed upsized $600 million zero-coupon exchangeable note offering; cash and investments totaled $815 million
- Brand 3 medical-grade dermatology launch on track for Q4 2025; Brand 4 development progressing toward 2026
- Raised FY2025 outlook to $799–804 million revenue (+23–24%) and $160–162 million adjusted EBITDA
Headline financials
Revenue & EPS history
ArcelorMittal · Revenue · Quarterly
$241M
Revenue by segment
ArcelorMittal · $241M total across 2 segments · Q2 2025
- Online direct-to-consumer$235M—97.5%
- Other (Israel retail, marketing affiliates)$5.98M—2.5%
Forward guidance
ODDITY raised FY2025 guidance to $799–804 million net revenue, ~71% gross margin, $160–162 million adjusted EBITDA, and adjusted diluted EPS of $2.06–2.09. Q3 2025 outlook is $144–146 million revenue, ~68% gross margin, $26–28 million adjusted EBITDA, and adjusted diluted EPS of $0.33–0.36.
Tailwinds
- Second consecutive beat-and-raise quarter with 25% revenue growth and strong DTC momentum
- Brand 3 launch in Q4 2025 opens medical-grade dermatology market
Headwinds
- Adjusted EBITDA margin declined 350 bps to 28.8% as investments increased
- Q3 revenue outlook implies slower sequential growth due to seasonality
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2025
+1.4%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+2.9%
Avg return
30 days after
56%
23 / 41 earnings
Positive
+13.9%
Q3 2022
Best reaction
-10.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2027 | -2.8% | -1.1% | — | |
| Q4 2026 | +2.3% | +4.0% | — | |
| Q3 2025 | +3.1% | +6.7% | +12.9% | |
| Q2 2025 | -5.6% | -4.4% | +2.8% | |
| Q4 2023 | +5.4% | -1.7% | -4.9% | |
| Q3 2023 | -3.6% | +1.7% | +11.6% | |
| Q2 2023 | -1.2% | +0.2% | -8.3% | |
| Q1 2023 | -3.4% | -1.9% | -4.6% | |
| Q4 2022 | -1.0% | +4.4% | +1.9% | |
| Q3 2022 | +13.9% | +11.6% | +12.3% | |
| Q2 2022 | +4.3% | -0.1% | -1.1% | |
| Q1 2022 | -6.1% | -6.5% | +10.2% | |
| Q4 2021 | -10.5% | -10.2% | -13.1% | |
| Q3 2021 | +1.6% | -1.7% | -5.6% | |
| Q2 2021 | +2.8% | +0.7% | +14.1% | |
| Q1 2021 | +7.0% | +8.3% | +7.7% | |
| Q4 2020 | -2.6% | +2.3% | +15.0% | |
| Q3 2020 | +5.7% | +11.7% | +50.9% | |
| Q2 2020 | -5.0% | -1.2% | +9.7% | |
| Q1 2020 | +8.7% | -18.5% | +10.3% | |
| Q4 2019 | +11.3% | +12.9% | -18.9% | |
| Q3 2019 | +7.5% | +7.5% | +13.0% | |
| Q2 2019 | -5.7% | -10.2% | -8.6% | |
| Q1 2019 | -5.6% | -11.8% | -21.5% | |
| Q4 2018 | -7.7% | -7.9% | -12.2% | |
| Q3 2018 | +2.5% | +3.7% | -7.7% | |
| Q2 2018 | -0.2% | -0.8% | -5.1% | |
| Q1 2018 | +2.9% | +2.6% | -6.3% | |
| Q4 2017 | -1.4% | -8.8% | -9.2% | |
| Q3 2017 | +3.1% | -0.8% | +11.2% | |
| Q2 2017 | +1.1% | -1.8% | +2.6% | |
| Q1 2017 | -3.5% | -4.9% | -9.0% | |
| Q4 2016 | +11.9% | +11.7% | +1.6% | |
| Q3 2016 | +2.1% | +3.1% | +26.4% | |
| Q2 2016 | +5.2% | +12.0% | +17.1% | |
| Q4 2015 | +9.9% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +0.8% | — | — | |
| Q1 2015 | -2.6% | — | — | |
| Q4 2014 | +6.3% | — | — | |
| Q3 2013 | +6.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro